Clinical Trial Detail

NCT ID NCT03820986
Title Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

Lenvatinib + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.